Business
Clene Reports First Quarter 2022 Financial Results and Recent Operating Highlights
Cash, cash equivalents, restricted cash and marketable securities of $36.6 million as of March 31, 2022Additional data from RESCUE-ALS presented at 2022 AAN
About this update from Clene Inc.
[{"type":"text","content":"Cash, cash equivalents, restricted cash and marketable securities of $36.6 million as of March 31, 2022Additional data from RESCUE-ALS presented at 2022 AAN Annual Meeting and MDA Clinical & Scientific Conference; Results show significant survival benefit in participants who entered open-label extension studyTop-line results from studies in ALS, MS and COVID-19 programs expected in third quarter SALT LAKE CITY, May 09, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today reported its first quarter 2022 and recent operating highlights. “As we approach the second half of 2022, we expect to report data readouts for our lead asset, CNM-Au8®, for the treatment of both ALS and MS,” said Rob Etherington, President and CEO of Clene. “Positive results from the Healey ALS Platform Trial would bring this potential new treatment option one step closer for people living with ALS.” First Quarter 2022 and Recent Operating Highlights CNM-Au8®, a gold nanocrystal suspension, for the treatment of amyotrophic lateral sclerosis (ALS) Top-line data from the HEALEY ALS Platform Trial, led by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, are expected in the third quarter of this year.Top-line results from the RESCUE-ALS Phase 2 clinical trial were reported in November 2021. Results demonstrated clinically meaningful benefits in people with early ALS. Additional data from the RESCUE-ALS open-label extension were presented in a late breaker session at the American Academy of Neurology Annual Meeting (April 2022). The data demonstrate a 70% survival benefit among ALS patients who entered the open-label extension (n=36, 90% of those eligible). The presentation is available in the Scientific Posters & Presentations section of the Clene website.Updated clinical trial results from RESCUE-ALS and REPAIR were presented at the Muscular Dystrophy Association Clinical & Scientific Conference (March 2022). Clene continues to support expanded access programs, providing CNM-Au8 treatment at four clinical sites for up to 55 total participants with ALS. CNM-Au8 for the treatment of multiple sclerosis (MS) Clene has initiated a se...